Passage Bio (NASDAQ: PASG) — Perfil da empresa, notícias e dados financeiros
Passage Bio develops genetic medicines for CNS disorders, aiming to transform treatment options for rare diseases.
Passage Bio
Passage Bio (NASDAQ:PASG) is a biotechnology firm at the forefront of developing genetic medicines targeting the central nervous system (CNS), with the aim of addressing rare, life-threatening disorders. The company's pipeline includes multiple gene therapy programs in various stages of development, each focusing on specific conditions such as GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease. By leveraging cutting-edge technology and innovative research strategies, Passage Bio strives to bring transformative treatments from the lab to patients in need. Their objective is to pioneer breakthrough therapies that can significantly improve the quality of life for individuals suffering from debilitating genetic diseases.
Resumo
Operações
Produtos e/ou serviços de Passage Bio
- Gene therapy targeting GM1 gangliosidosis, a severe neurological disorder, aimed at delivering functional genes directly into patients' brains.
- Treatment for Krabbe disease via gene therapy, designed to halt disease progression by replacing defective genes.
- A therapeutic candidate for Frontotemporal Dementia, aiming to restore normal gene function in patients' brains.
- Development of a gene editing tool to potentially correct genetic defects in a range of inherited diseases.
- Research into innovative delivery mechanisms for gene therapies, enabling more efficient and targeted treatment.
- Collaborative efforts with academic and research institutions to discover new gene therapy techniques and applications.
equipe executiva do Passage Bio
- William ChouPresident, CEO & Director
- Kathleen BorthwickSenior VP, CFO, Principal Financial Officer & Principal Accounting Officer
Últimas notícias sobre a Passage Bio
Principais indicadores financeiros
Resultados divulgados pela Passage Bio, em USD.
- Cap. de mercado
- 10,8 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -11.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -43,2 mi | -45,5 mi | |
| 0 | -70,4 mi | -64,8 mi | |
| 0 | -100,1 mi | -102,1 mi | |
| 0 | -138,4 mi | -136,1 mi |